EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer
The combination of masofaniten and enzalutamide for treatment-naïve mHSPC did show efficacy and had an acceptable safety profile. These results support further investigation of the dual AR blockade in mHSPC (ClinicalTrials.gov Identifier: NCT06312670).
Authors
- Karen Villaluna
- Abby Grier (ORCID: https://orcid.org/0000-0002-5199-8670)
- Albert Jang (ORCID: https://orcid.org/0000-0002-0461-6174)
- J GARCIA
- Seunghee Margevicius (ORCID: https://orcid.org/0000-0001-5663-8319)
- Christopher Eing Wee (ORCID: https://orcid.org/0000-0003-0168-2069)
- Jeffrey Zhong (ORCID: https://orcid.org/0009-0008-1711-3155)
- P. Fu
- Pedro Coelho Barata (ORCID: https://orcid.org/0000-0002-8890-2951)
- Tanya Jindal (ORCID: https://orcid.org/0000-0001-5954-3278)
- Jason Robert Brown (ORCID: https://orcid.org/0000-0001-6225-7555)
- Brett S. Younginger (ORCID: https://orcid.org/0000-0002-7297-2226)
- Prateek Mendiratta
- Rishi Patel (ORCID: https://orcid.org/0000-0002-2797-4206)
- Mary Hislop
- Amy L. Reese (ORCID: https://orcid.org/0009-0007-7403-5336)
- Iris Yeong- Fung Sheng (ORCID: https://orcid.org/0009-0007-4999-6733)
- Kathryn Helminiak
- Hannah Garcia
- Shilpa Gupta
- Amanda Nizam
- Julie Bray
- Hamsa L S Kumar
- Timothy Adamowicz
- Jeffrey Pasucal
- Kayla Wolff
- Kara Richey
- Victoria Delong
- Peggy Fowler
- Alessandra Cesano
Institutions
- National Academy of Governance (MN)
- Cleveland Clinic (US)
- University Hospitals of Cleveland (US)
- Firelands Regional Medical Center (US)
- Essa Pharma (United States) (US)
- University Hospitals Cleveland Medical Center (US)
- University Hospitals Seidman Cancer Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1093/oncolo/oyaf434
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52